Americafirst Capital Management LLC bought a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,276 shares of the specialty pharmaceutical company’s stock, valued at approximately $434,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EGRX. Teachers Advisors LLC lifted its stake in Eagle Pharmaceuticals by 2.4% during the first quarter. Teachers Advisors LLC now owns 15,917 shares of the specialty pharmaceutical company’s stock worth $1,320,000 after purchasing an additional 380 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Eagle Pharmaceuticals by 5.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 36,316 shares of the specialty pharmaceutical company’s stock worth $3,013,000 after buying an additional 1,875 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Eagle Pharmaceuticals by 2.3% during the first quarter. Bank of America Corp DE now owns 14,765 shares of the specialty pharmaceutical company’s stock worth $1,225,000 after buying an additional 334 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Eagle Pharmaceuticals by 323.9% during the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 1,908 shares in the last quarter. Finally, Aperio Group LLC acquired a new position in shares of Eagle Pharmaceuticals during the second quarter worth $282,000.

Several brokerages have recently issued reports on EGRX. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Mizuho lowered their price target on shares of Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating for the company in a report on Wednesday, September 6th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $62.33.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $58.73 on Thursday. The firm has a market capitalization of $890.52, a price-to-earnings ratio of 9.41 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a 1-year low of $45.05 and a 1-year high of $97.15. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26.

TRADEMARK VIOLATION NOTICE: “Americafirst Capital Management LLC Invests $434,000 in Eagle Pharmaceuticals, Inc. (EGRX) Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/americafirst-capital-management-llc-invests-434000-in-eagle-pharmaceuticals-inc-egrx-stock/1762756.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.